Lupin
Lupin Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
What the Q1 FY27 call signalled
1 of 3 strong
The short version
Europe is expected to grow at a 10%-20% level, with South Africa slightly lower. - Rest of World (ROW) markets also anticipated to continue double-digit growth. - U.S. Lupin expects U.S.
From Lupin's Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- Europe is expected to grow at a 10%-20% level, with South Africa slightly lower.
- Rest of World (ROW) markets also anticipated to continue double-digit growth.
- U.S. sales projected to return to growth trajectory from FY28, building on a base of USD 1.1-1.2 billion in FY27.
- U.S. portfolio complexity to double in 3-5 years with 50+ planned product launches including exclusive first-to-files, biosimilars, and 505(b)(2) products.
- India business growing 13.9% YoY, core prescriptions growing 15.1%, outperforming market by 1.1x, targeting 1.2x-1.3x IPM growth.
- India aims for one-third revenue from innovative products over next 10 years with 60-70 product launches.
2 more points management made on revenue & sales performance
Profitability & Margins
See what Lupin said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Lupin has allocated capital for innovation in India, focusing on developing 30-50 assets at a time and aiming for one-third of India revenues from innovative products over 10 years.
- A small but commercial investment is planned, particularly in the U.S., for the biosimilars business and 505(b)(2) products like Apixaban.
- Investment is also ongoing in expanding the biosimilars portfolio, specialty acquisitions (e.g., VISUfarma), and complex generics in Europe and the U.S.
- Incremental investments in key markets are expected to maximize pipeline opportunities, including commercial investments for 505(b)(2) filings.
2 more points management made on capital expenditure plans
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Lupin said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points management made on order book & pipeline
Lupin — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹7.5K Cr, net profit ₹1.5K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Lupin Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules Ltd (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
- Aptus Pharma Ltd (Q1 FY27)
Revenue from Operations for H2 FY26: ₹32.20 crore, up 117.5% YoY from ₹14.80 crore in H2 FY25 (Page 23) . Key concall takeaways from Aptus Pharma Ltd's Q1 FY27…
- RPG Life Sciences Ltd (Q1 FY27)
Q1 FY27 Revenue from Operations: ₹195.7 crores, up 15.8% YoY (Q1 FY26: ₹168.9 crores) [Page 18] . Key concall takeaways from RPG Life Sciences Ltd's Q1 FY27…
- SMS Pharmaceuticals Ltd (Q1 FY27)
Q1FY27 revenue from operations: ₹207 crore, up 6% YoY (Page 6, 5) . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Lupin Q1 FY27 results?
Europe is expected to grow at a 10%-20% level, with South Africa slightly lower. - Rest of World (ROW) markets also anticipated to continue double-digit growth. - U.S. Lupin expects U.S.
What is Lupin share price analysis?
Lupin currently shows a below-average growth signal. The stock trades at a P/E of 16.0 with a market cap of ₹95,248 Cr. Investors should review the full earnings analysis for detailed insights.
Is Lupin planning capital expenditure?
Lupin has allocated capital for innovation in India, focusing on developing 30-50 assets at a time and aiming for one-third of India revenues from innovative products over 10 years. - A small but commercial investment is planned, particularly in the U.S., for the biosimilars business and 505(b)(2) products like Apixaban. - Investment is also ongoing in expanding the biosimilars portfolio, specialty acquisitions (e.g., VISUfarma), and complex generics in Europe and the U.S. - Incremental investments in key markets are expected to maximize pipeline opportunities, including commercial investments for 505(b)(2) filings. - Lupin is also making manufacturing investments, such as leveraging domestic U.S.
Keep Lupin on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.